Oncomine Dx Express Test
Life Technologies Corporation · Decision date Nov 4, 2026
What did the FDA approve?
The FDA recorded approval on 2026-11-04 for P240040/S008, a supplement to the Oncomine Dx Express Test held by Life Technologies Corporation. The supplement is classified as a real-time process submission with a recorded reason of change to design, components, specifications or materials. The device category is a next generation sequencing oncology panel for somatic or germline variant detection, under product code PQP in the pathology specialty.
The recorded scope is narrow: approval covers Genexus Dx Software Security Patch version 6.8.2.2, intended to address vulnerabilities discovered in the Genexus Dx Software. This is a software component change within the existing application, not a new approval of the whole test system, and the source does not describe analytical or clinical performance data, affected assay functions, or the nature of the vulnerabilities. Whether the patch alters test performance or requires customer action is not stated in the available record.
FDA approval order statement
Approval for Genexus Dx Software Security Patch version 6.8.2.2 to address the vulnerabilities discovered on the Genexus Dx Software.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Pathology
- Decision date
- Nov 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240040/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240040 · Original PMA
Oncomine Dx Express Test
P240040/S008 received
Application receipt date recorded by FDA.
P240040/S005 · Related supplement
Oncomine Dx Express Test
P240040/S008 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040 | Life Technologies Corporation | PMA approval | Jul 2, 2025 | FDA |
Oncomine Dx Express TestP240040/S005 | Life Technologies Corporation | PMA supplement | Sep 9, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7335 Executive Way, Frederick, MD, 21704
Sources and methodology
- Original FDA record: P240040/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



